Ascentage Pharma Group International American Depository Shares (AAPG)

Ascentage Pharma reported strong sales growth for Olverembatinib, received approval for Lisaftoclax in China, and completed a top-up placement raising $190.1 million in net proceeds. The company continues advancing nine registrational clinical trials across multiple cancer therapies.

Several mid-cap companies, including Bitdeer Technologies, Tempus AI, Ascentage Pharma, Ardagh Metal Packaging, and Pegasystems, saw significant gains last week due to factors such as better-than-expected financial results, positive data presentations, and overall market strength.